Fact Source: Financial Supervisory Service DART / 2024-12-17
Disclosure Type: Execution of Single Sales/Supply Contract
💡 3-Second Summary
SAMSUNG BIOLOGICS has executed a contract manufacturing organization (CMO) agreement worth approximately KRW 111.3B (USD 77.5M) with a U.S.-based pharmaceutical firm, representing 3.01% of its consolidated annual revenue from the 2023 fiscal year.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Contract Name: Contract Manufacturing Agreement for Pharmaceuticals (Other Sales/Supply Contract)
- Contract Amount: KRW 111,267,885,600 (Confirmed amount: USD 77,544,000)
- Applied Exchange Rate: Fixed at the initial base rate of USD/KRW 1,434.90 as of December 17, 2024.
- Ratio to Recent Revenue: 3.01% (Recent annual revenue based on 2023 consolidated financial statements: KRW 3,694,588,767,068)
- Counterparty: A pharmaceutical company located in the United States (Identity withheld until October 2, 2030, due to operational confidentiality).
- Contract Period: From December 17, 2024 (Commencement Date and Contract Date) to October 2, 2030 (Expiration Date).
- Key Terms: No down payment or advance payment is provided (None).
- Regulatory Note: The contract expiration date and the scheduled counterparty disclosure date remain subject to change upon mutual agreement between both parties.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This supply contract serves as a performance indicator demonstrating that SAMSUNG BIOLOGICS is continuously expanding its portfolio execution capacity within the United States, the world’s largest pharmaceutical market. While the ratio to historic revenue (3.01%) represents a routine addition rather than a massive catalyst, it documents that the company’s manufacturing pipeline maintains stable client acquisition momentum.
From an analytical standpoint, international macro investors should prioritize foreign exchange structures and revenue recognition timelines. Because the contract is locked in USD (USD 77.54M), executing the transaction during a favorable USD/KRW macro threshold of 1,434.90 expands the initial KRW-converted values. Final realized revenue metrics may fluctuate depending on currency dynamics at the time of actual production and delivery. Furthermore, given the nearly six-year duration spanning from late 2024 through October 2030, this backlog will be recognized progressively based on manufacturing milestone completions and facility allocation schedules rather than in an immediate quarterly surge.
The filing does not provide qualitative metrics regarding specific product types or exact profit margin structures due to strict confidentiality parameters. However, anchoring a stable operational backlog with a U.S. client expands the company’s global validation record, acting as a supportive variable for institutional asset allocations.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS has sustained its order momentum by booking a new KRW 111.3B CMO contract in the U.S. theater. While accounting for a modest 3% of the legacy annual revenue floor, securing a USD-denominated contract (USD 77.5M) when the macro conversion rate hovers above 1,430 provides management with a stable FX translation framework for the initial entry.
Although the counterparty remains unmapped under standard confidentiality clauses until 2030, the transaction reflects the continuous demand from U.S. market participants for the company’s audited manufacturing capacities. Institutional analysts should look past near-term quarterly expectations, as this backlog is engineered for progressive conversion across a six-year window. The primary value driver is the continuous optimization of facility utilization rates, which effectively supports long-term asset efficiency and cash flow durability.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
